New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg;   - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg   excipient: acid yellow 17 brilliant blue fcf colloidal silicon dioxide erythrosine gelatin indigo carmine lactose monohydrate magnesium stearate maize starch purified talc sodium laurilsulfate titanium dioxide   water - - depression and its associated anxiety

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg;   - dispersible tablet - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg   excipient: colloidal silicon dioxide crospovidone magnesium stearate maize starch mentha x piperita microcrystalline cellulose saccharin sodium - in adults 18 years of age and over: - depression and its associated anxiety - bulimia nervosa - obsessive-compulsive disorder - premenstrual dysphoric disorder - a severe form of pms diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptom (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: dimeticone gelatin ink iron oxide yellow patent blue v starch titanium dioxide - · depression and it's associated anxiety · bulimia nervosa · obsessive-compulsive disorder and premenstrual dysphoric disorder - a severe form of pms. diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptoms (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - dispersible tablet - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: aniseed colloidal silicon dioxide crospovidone mannitol mentha x piperita microcrystalline cellulose saccharin sodium sodium stearyl fumarate sorbitol starch - depression and it's associated anxiety, bulimia nervosa, obsessive-compulsive disorder and premenstrual dysphoric disorder - a severe form of pms. diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptoms (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: dimeticone gelatin indigo carmine ink quinoline yellow starch

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg - dispersible tablet - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg excipient: aniseed colloidal silicon dioxide crospovidone mannitol mentha x piperita microcrystalline cellulose saccharin sodium sodium stearyl fumarate sorbitol starch

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: pregelatinised maize starch; gelatin; purified water; sodium lauryl sulfate; allura red ac; quinoline yellow; titanium dioxide; brilliant blue fcf - major depression. obsessive compulsive disorder. premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria.

United States - English - NLM (National Library of Medicine)

contract pharmacy services-pa - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine hydrochloride 20 mg - fluoxetine is indicated for the treatment of major depressive disorder. adult - the efficacy of fluoxetine was established in 5 and 6 week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the dsm-iii (currently dsm-iv) category of major depressive disorder (see clinical trials ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the effects of fluoxetine in hospitalized depressed patients have not been adequately studied. the efficacy of fluox

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: maize starch; purified talc; sodium lauryl sulfate; lactose monohydrate; gelatin; colloidal anhydrous silica; magnesium stearate; brilliant blue fcf; titanium dioxide; erythrosine; quinoline yellow; indigo carmine; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - indicated for the treatment of major depression. obsessive compulsive disorder (ocd).

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - capsule, hard - excipient ingredients: iron oxide yellow; titanium dioxide; pregelatinised maize starch; gelatin; dimeticone 350; patent blue v; indigo carmine; butan-1-ol; shellac; iron oxide black - prozac is indicated for the treatment of: major depression. obsessive complusive disorder. premenstrual dysphoric disorder (pmdd) as defined by dmv-iv criteria. the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.